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ABSTRACT
HARDINESS AND ITS RELATIONSHIP TO
ANTICIPATORY NAUSEA AND VOMITING EXPERIENCED
BY THE PATIENT RECEIVING CISPLATIN CHEMOTHERAPY
By
Colleen K. Smith
Research suggests that the hardiness characteristic
acts as a buffer in the stress/illness relationship.
The purpose of this study was to assess the presence of
hardiness and examine its relationship to the amount of
anticipatory nausea and vomiting experienced within a
sample of patients receiving cisplatin chemotherapy.
It was hypothesized that individuals with a high level of
hardiness would experience less anticipatory nausea and
vomiting than individuals with a low level of hardiness.
A prospective descriptive correlational design was
utilized.

A convenience sample of adults with cancer

(n=29) receiving cisplatin intravenously was studied.
patients were assessed via two measurement tools:

All

the

Health Related Hardiness Scale (Pollock, 1984) and the
Rhodes Index of Nausea and Vomiting Form 2 (Rhodes,
Watson, Johnson, Madsen, & Beck, 1987).

The hypothesis

was not supported as being statistically significant,
however, there was a greater tendency for those who were
hardy to experience less anticipatory nausea and vomiting.
ii

ACKNOWLEDGMENTS

This research would not have been completed without
the assistance and cooperation of my committee members.
I am grateful to Patricia Underwood, PhD, RN, who served
not only as the chairperson of my committee, but also as
a coach and a mentor.

Her patience and positive feedback

served as key motivators throughout this process.

I want

to thank Kay Reick, MS, RN, for her expertise in oncology
and warm words of encouragement, and Rodney Mulder, PhD,
for his objectivity and support.
Appreciation is also extended to Cynthia Coviak,
MSN, RN, an invaluable resource during the data analysis
process.

Her patience and willingness to teach greatly

enhanced my understanding of statistics.
I would also like to extend my appreciation to Denise
J. Bakker, BSN, RN, Brenda J. Bartz, BSN, RN, OCN, and
Rose Yancey, MSN, RN, OCN, the oncology nurses who
participated as data collectors for this study.

Their

persistence and support was essential to the completion of
this project.
This research was partially funded through the
Elizabeth R. Hughes Nursing Study Grant, American Cancer
Society, Michigan Division, Inc.
iii

Table of Contents

List of

Tables....................................... vi

List of Figures...................................... viii
List of Appendices................................... ix
CHAPTER
1

INTRODUCTION...................... ........... 1

2

LITERATURE AND THEORY......................... 4
Literature Review........................ 4
Theoretical Framework.........

16

Definition of Terms...................... 20
Hypothesis................................ 21
3

METHODOLOGY......................

23

Research Design.............

23

Sample and Setting........................23
Instruments............................... 24
Procedure.
4

............................28

DATA ANALYSIS.................. .............. 3 3
Characteristics of Subjects.............. 34
Analysis of the Research Hypothesis.......46
Additional Findings ofInterest........... 47

IV

5

DISCUSSION AND IMPLICATIONS.................... 51
Discussion.................... ............. 51
Limitations. .............................. 57
Implications forNursingPractice............ 61
Recommendations for Further Research........ 63
Conclusion............ .................... 65

List of References...................................... 82

List of Tables

Table
1

Comparison of Alpha Coefficients from HEHS and
Kobasa's Hardiness Scale....................... 26

2

Distribution

of Sample Based on Data

Collection S ite................................. 35
3

Distribution

of Sample by Ethnicity............ 3 6

4

Distribution

of Sample by Education............ 37

5

Distribution

of Sample Based on Primary Site of

Cancer.......................................... 38
6

Distribution of Sample Based on Dose of
Cisplatin.............

7

..39

Distribution of Sample by Nausea Experienced
One Week After Chemotherapy.................... 41

8

Distribution of Sample by Vomiting Experienced
One Week After Chemotherapy.................... 42

9

Distribution of Sample by Frequency of
Medication Taken for Nausea & Vomiting One Week
After Chemotherapy..............................42

10

Mean Scores of the HRHS and Subscales.......... 44

VI

11

Mean Scores for the INV Form 2 and Selected
Subscales....................................... 45

12

Correlations Between HRHS Subscales and INV
Form 2 Totals...................

13

47

Relationship Between Presence of Hardiness and
Anticipatory Nausea and Vomiting.............. 50

Vll

List of Figures

Figure
1

Model of Conceptual Framework.................21

2

Time Line of Interaction With Subjects....... 31

Vlll

List of Appendices

Appendix
A

Demographic and Related Data....................66

B

Chart Review Former............................. 69

C

Patient Questionnaire........................... 71

D

Health Related Hardiness Scale..................73

E

Rhodes Index of Nausea and Vomiting Form 2 ..... 76

F

Introductory Statement.......................... 77

G

Consent to Participate in Study.................79

H

Cover Letter.

..................

XX

81

CHAPTER ONE
INTRODUCTION
Oncology patients provide a multitude of diverse
challenges for the health care practitioner.

Many of

these challenges arise from the illness trajectory
induced by the cancer itself, while others arise from
the treatment regime employed to combat the cancer.

One

identified treatment induced challenge is that of
anticipatory nausea and vomiting associated with
chemotherapy.
Many patients receiving the same or similar
chemotherapeutic drugs experience wide differences in
side effects.

Nausea and vomiting have long been

identified as two of the most frequently experienced
side effects of chemotherapy.

This includes nausea and

vomiting that result from the anticipation of treatment.
As with other chemotherapy side effects, a wide range in
the frequency, intensity, and duration of anticipatory
nausea and vomiting can be observed from patient to
patient.
Research to date has not provided definitive
answers to explain why one individual tolerates a
particular chemotherapeutic agent better than another

individual receiving the same drug.

Nursing recognizes

one of its goals as offering competent individualized
care to clients and, therefore, must delve into issues
that may explain why each individual responds
differently.

By identifying factors that influence

individual responses, interventions that support
individualized nursing care can be identified.
One factor that requires further exploration is
that of hardiness.

Kobasa (1979) initially identified

hardiness as a personality characteristic that may act
as a buffer, or resistance factor, in preventing
illness.

Anticipatory nausea and vomiting result as

undesirable responses to chemotherapy.

If the

hardiness characteristic does act as a resistance factor
to prevent the development of anticipatory nausea and
vomiting, it is essential that further research explore
this quality.

Identification of such resistance factors

may aid patients in the management and reduction of
anticipatory nausea and vomiting due to chemotherapy.
The purpose of this study was to assess the presence
of the hardiness characteristic and examine its
relationship to the amount of anticipatory nausea and
vomiting experienced within a sample of patients
receiving cisplatin as their primary chemotherapeutic
agent.

Knowledge of this relationship may facilitate

the identification and utilization of psychophysiological nursing interventions to assist the cancer
patient experiencing anticipatory nausea and vomiting.

CHAPTER TWO
LITERATURE AND THEORY
Literature Review
Advances in cancer therapy have provided reason for
hope and actual cure in many patients.

Chemotherapy is

a modality of treatment for cancer that offers improved
outcomes, but in addition, a multitude of side effects.
These side effects can affect not only the quality of
life for the cancer patient, but also the compliance
with the individual treatment regime.

Anticipatory

nausea and vomiting is one such undesirable side effect
that can influence the patient's compliance with cancer
therapy.
The development of anticipatory nausea and vomiting
has been identified in terms of classical conditioning.
Pratt, Lazar, Penman, and Holland (1984) describe this
process.

The chemotherapeutic agent, identified as the

unconditioned stimulus, produces an unconditioned
reflexive response, nausea and/or vomiting.

If

extraneous factors, such as odors or surroundings,
become paired with the unconditioned stimulus, these
previously innocuous stimuli then become conditioned
stimuli.

The responses which result from conditioned

stimuli are identified then as conditioned responses.
Therefore, when the patient receiving chemotherapy
experiences nausea and vomiting, often neutral
stimuli become paired with the chemotherapy induced
nausea and vomiting.

After repeated experiences, the

patient experiences nausea and may vomit when simply
exposed to the neutral stimuli.
Nerenz, Leventhal, Easterling, and Love (1986)
present a conditioned anxiety model to explain the
development of anticipatory nausea and vomiting.

This

model identifies anticipatory nausea and vomiting as the
result of an emotional state or aversion that is a
conditioned response to external stimuli.

Interview

data obtained from 192 patients receiving chemotherapy
for the first time was analyzed to identify predictive
factors for the development of anticipatory nausea and
vomiting.

Three predictors were identified;

post

treatment nausea and vomiting, tastes of drugs during
injections, and anxiety before injections.

Although

this study was limited due to the use of retrospective
interview methodology and a broad definition of
anticipatory nausea and vomiting, evidence was elicited
to suggest that anxiety resulting from post-treatment
nausea and vomiting did facilitate the later development
of anticipatory nausea and vomiting.

Goodman (1987) states that as a result of postchemotherapy nausea and vomiting, particularly with
cisplatin as the primary chemotherapeutic agent,
effective antiemetics must be utilized.

If inadequate

antiemetic therapy is used, fear and anxiety result.
This fear and anxiety subsequently become the
conditioned response to chemotherapy and anticipatory
nausea and vomiting are more likely to result.
The reported prevalence and related influencing
variables of anticipatory nausea and vomiting have
varied in the research to date.

Morrow (1982) reported

twenty-one percent (47 of 225 patients) as having
experienced anticipatory nausea and vomiting prior to a
chemotherapy treatment.

Examination of demographic and

clinical factors determined that patients with
cnticipatory nausea and vomiting experienced severe
post-treatment vomiting, experienced severe nausea after
treatment, and were more likely to be receiving cisplatin
than patients without anticipatory side effects.
Reporting an incidence of one in four patients who
experience anticipatory nausea and vomiting by the time
of their fourth treatment. Morrow (1984) conducted a
study to identify characteristics of patients at a high
risk for developing anticipatory nausea and vomiting.

The identified characteristics were:
(1) less than 50 years of age; (2) the experience
of nausea and/or vomiting after their last
chemotherapy treatment; (3) a description of nausea
after the last treatment as "moderate, severe, or
intolerable"; (4) a description of vomiting after
the last treatment as "moderate, severe, or
intolerable"; (5) the reporting of the side effect
"warm or hot all over" after their last treatment;
(6) a susceptibility to motion sickness;

(7) the

experience of "sweating after the last treatment";
(8) and the experience of "generalized weakness
after the last chemotherapy treatment" (p. 1170).
Patients who experienced anticipatory nausea and
vomiting were significantly more likely (p<.001 using the
Chi-square test) to have four or more of these
characteristics.
Coons, Leventhal, Nerenz, Love, and Larson (1987)
studied thirty-four patients receiving cisplatin-based
chemotherapy.

This study was conducted to determine the

percentage of patients who experienced anticipatory
nausea, to assess factors associated with the development
of anticipatory nausea, and to examine the affect of
anticipatory nausea on emotional distress with treatment.
All subjects experienced post-treatment nausea and/or

vomiting.

Anticipatory nausea was experienced by sixty-

five percent of the sample in one or more situations.
Patients who experienced any anxiety during their first
injection reported a somewhat higher frequency of
anticipatory nausea than those who were not anxious,
however, the study failed to achieve statistical
significance in this relationship.

This was due primarily

to the limitation of a small sample size.
Andrykowski et al. (1988) studied factors related
to the prevalence, prediction, and course of
anticipatory nausea in women (N=77) receiving adjuvant
chemotherapy for breast cancer.

Via a prospective

longitudinal research design, patients were interviewed
before and after each chemotherapy treatment.

Findings

indicated fifty-seven percent of the patients developed
anticipatory nausea.

Two important factors influencing

this development were the severity and duration of post
treatment nausea following the initial infusion and the
patient's expectations for experiencing nausea.

While

the results of the study indicate that anxiety levels at
the initial infusion were not associated with the future
likelihood of developing anticipatory nausea, it was
suggested that anxiety appears to contribute to the
development of anticipatory nausea in patients who have
not already developed it following the initial infusion.
8

It is suggested that anticipatory nausea could be
prevented or delayed through improved control of anxiety
during the chemotherapy treatment course.
Stefanek, Sheidler, and Fetting (1988) assessed the
prevalence of anticipatory nausea and vomiting in patients
(N=121) who received intravenous chemotherapy over a
seven week period. Ten percent (12) of the subjects
received cisplatin-containing regimens.

This study was

conducted via cross-sectional prevalence methodology.
They reported a prevalence ratio of thirty-three percent,
with the length of post-chemotherapy nausea as
significantly related to the development of anticipatory
symptoms.

However, they identified that the severity of

anticipatory symptoms was very mild to mild.

This

study concluded that anticipatory nausea and vomiting is
not a significant clinical problem for a large majority of
patients receiving chemotherapy, however, a significant
minority of patients experience anticipatory symptoms.
In summation, a review of the research revealed
several factors which have an impact on the development of
anticipatory nausea and vomiting.

Relevant factors were

post-treatment nausea and vomiting, fear and anxiety
that result from treatment, and the chemotherapeutic
agent used for treatment.

cisplatin is recognized as a highly emetogenic drug,
and the literature identifies highly emetogenic agents as
contributing to the development of anticipatory nausea and
vomiting (Briscoe, 1989; Coons, Leventhal, Nerenz, Love, &
Larson, 1987; Clark, 1989; Duigon, 1986; & Hogan, 1990).
While cisplatin has become an instrumental
chemotherapeutic agent, its success has been influenced by
the often times severe nausea and vomiting that occurs in
most patients who receive this drug (Goodman, 1987).
Nausea and vomiting may be severe and often begin one to
six hours after the administration of the drug and can
persist up to twenty-four hours or longer (McEvoy, 1990).
It becomes essential to intervene with the symptomatology
of nausea and vomiting that result from this agent in an
effort to increase patient comfort and compliance.
If nursing interventions are to be effective, an
examination of all factors that have an impact on the
development of anticipatory nausea and vomiting should
occur.

This includes an examination of factors that may

buffer, thereby reduce, the untoward response identified
as anticipatory nausea and vomiting.

One factor that may

act as a buffer is the personality factor hardiness.
A search of the relevant nursing and medical
literature revealed no studies examining the individual
hardiness characteristic specifically related to cancer or
10

to the side effects resulting from therapy for cancer.
Carey, Oberst, McCubbin, and Hughes (1991) utilized the
concept of family hardiness in an exploratory study to
examine appraisal and caregiving burden in family members
caring for patients receving chemotherapy.

Family

hardiness was again examined in relationship to the
appraisal of illness, symptom distress, self-care burden,
and mood states in patients receiving chemotherapy for
intial and recurrent cancer (Munkres, Oberst, and Hughes,
1992).

While these studies examined family hardiness,

they do not address individual hardiness, the focus of
this study.

There were, however, a number of studies that

explored the hardiness characteristic in relationship to
stress, illness, and adaptation.
Kobasa (1979) utilized a retrospective descriptive
correlational design to examine stressful life events,
personality, and health.

Two groups were refined from a

large subject pool (N=827) that consisted of all middle
and upper level executives of a large public utility.
The groups were divided based on the completion of a
stress and illness questionnaire.

Group one (N=86)

consisted of executives who suffered high stress/low
illness.

Group two (N=75) consisted of executives who

suffered high stress/high illness.

These groups were

then administered a composite of several personality
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tests to evaluate personality characteristics (including
hardiness) and their relationship to stress and health.
The findings, as they related to stress and illness,
showed a weak, but significant correlation (r=.24, p<.025)
between stress and illness.

Kobasa did support her

hypothesis that the high stress/low illness executives
had a higher level of hardiness than the high
stress/high illness executives.

The limitations of this

study included self-report measures for data collection
and potential distortion of findings due to a variable
identified as illness behavior;

Subjects want to act and

behave as if they are ill and thus report themselves as
ill.
Pollock (1586) hypothesized that the presence of
the hardiness characteristic would correlate with
physiological adaptation in chronically ill adults.
A convenience sample (N=60) of male and female adults
diagnosed with adult onset illness for at least one year
was identified.

The sample was divided into three equal

groups based on diagnosis:

insulin dependent diabetes

mellitus (N=20), essential hypertension (N=20), and
rheumatoid arthritis (N=20).

Physiological adaptation

was measured via a scale specific to each of the three
identified diagnoses.

Hardiness was measured by the

Health Related Hardiness Scale developed by Pollock in
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1984.

Results of this study indicated that the presence

of hardiness was related to adaptive behavior in the
diabetic group, but not in the arthritic or hypertensive
group.

The small sample size in each diagnostic category

was identified as a limitation in this study, along with
the difficulty of examining common elements in these
diagnostic categories without accounting for the
differences between categories.
Schmied and Lawler (1986) used a correlational design
to examine the relationships among stress, illness,
hardiness, and Type A behavior in a convenience sample
(N=82) of female secretaries.

The findings indicated a

strong positive relation between stress and illness with
no relation between Type A behavior and illness
(F(l,72)=3.67, p=.05). In addition, there were no
hardiness effects or interactions between stress. Type A
behavior, and hardiness.

One of the primary limitations

of this study is that one cannot generalize from the
secretarial work force response to all working women, thus
its application is limited.
Using a correlational design. Rich and Rich (1987)
examined the burnout-moderating effects of the hardiness
characteristic in female staff nurses.

A convenience

sample (N=100) of staff nurses was studied.

This group of

nurses had at least one year of experience as a staff
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nurse in an acute care hospital in western Pennsylvania.
The results of this study supported the hypothesis that
personality hardiness is an important stress-resistance
attribute in preventing or reducing burnout in female
staff nurses. The education level of the nurses in this
study was obtained as a demographic variable, but was not
discussed as a possible influence on burnout.

Another

limitation identified was that this sample was taken from
only one hospital with no mention of benefits and/or work
environment that may have influenced burnout in the
sample.
Banks and Gannon (1988) conducted a prospective
study to examine the potential of hardiness as a
mediator in the relationship between stress and
symptoms.

Thirty male and fifty-eight female students

received questionnaires on four separate occasions at
one-month intervals. Results indicate that hardiness
tended to have additive and opposite effects in looking
at it as a mediator between stress and symptoms.

Those

with a higher hardiness level experienced stress less
often and perceived minor events as less stressful.
Limitations include the use of self-reported measures
and a short prospective period of assessment.
In a survey of women with rheumatoid arthritis
(N=122), Lambert, Lambert, Klipple, and Mewshaw (1989)
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explored the ability of social support and hardiness to
predict psychological well-being.

Subjects were

administered three questionnaires via interviews, with
results suggesting that both satisfaction with social
supports and the presence of hardiness were factors that
enhance coping with a chronic debilitating disease.
Limitations of the study include the restricted usefulness
of determining causal effects with the exploratory survey
design, and the inability to generalize findings as the
subjects were primarily Caucasian, well educated, and from
a high socioeconomic background.
Ross (1991) conducted a study to determine if the
presence of hardiness influenced compliance in elderly
patients with diabetes (N=50).

The Health Related

Hardiness Scale (HRHS), developed by Pollock, was utilized
to measure hardiness.

The Self-Management Compliance

Questionnaire was administered to measure compliance with
the prescribed diabetic regime.

The Pearson r correlation

coefficient was calculated to demonstrate a significant
relationship between the total HRHS score (r=-.60, p,.05)
and compliance.

The results of this study suggest that

the degree of hardiness in individuals with diabetes may
predict compliance to a prescribed diabetic regimen.

A

limitation to this study was the inability to generalize
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the findings as the subjects were primarily white, male,
married, and diagnosed with Type II diabetes.
It is determined from these studies that there does
exist a relationship between stress and illness and that
hardiness may act as a mediator in the stress/illness
link, however, more research is needed to support
previous research and to further examine the hardiness
characteristic and its relationship to both stress and
illness.
Theoretical Framework
The development of anticipatory nausea and
vomiting has been described in the literature via the
classical conditioning model and the conditioned anxiety
model.

However, symptom development can also be

approached from a stress theory framework.

Few would

dispute that cancer and its treatment are a source of
anxiety and stress.

Lindsey and Carrieri (1986) identify

stress as a sociopsychophysiological phenomenon, therefore
an interaction of physiologic, mental, and behavioral
responses to a stressor of some type.

Lindsey and

Carrieri further identify stress as an integrated
hypothalamic response that is subject to the strength of
the stimulus (stressor) and is modified by specific
individual characteristics such as age, sex, and previous
experience.

The stress response is identified as a
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protective adaptive function (Lindsey & Carrieri, 1986)
unless the stressor is prolonged or severe, in which
case illness or maladaptation occurs.
The life stress and illness model (Rahe, 1988)
identifies a series of steps to represent the sequence
of events from exposure of a life stressor to the
development of illness.
1.

Life events may be altered based on an

individual's perception of these events.
2.

Psychological defense mechanisms can be

utilized to buffer the impact of a life stressor,
however, these defenses are not adaptive for extensive
periods of time.
3.

If a life stressor cannot be buffered, the

stressor may persist to stimulate physiological
reactions.
4.

If an individual is aware of these

psychophysiological responses, and the responses are
perceived as a threat to health, they become symptoms.
5.

When the individual's ability to cope is

inadequate, and the symptoms become prolonged and
severe, anxiety and illness result.
The life stress and illness model supports the
relationship between stressor and symptom in the cancer
patient receiving chemotherapy.
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The stressor may be

identified as the chemotherapeutic agent administered to
the patient.

Often the agent produces nausea and

vomiting post-treatment, which acts to reinforce the
agent as a stressor.

The psychophysiologic response to

this stressor, if unbuffered, may result in the symptom
of anticipatory nausea and vomiting.
It must be recognized that a number of factors
interface to produce the individual's perception of the
stressor.

Often an individual's perception evolves from

both life events and individual personality attributes.
Kobasa (1979) proposed that people who experience high
degrees of stress without falling ill may have a
specific personality characteristic that differentiates
them from people who do become sick under stress:
hardiness is that characteristic.

The hardiness

characteristic, therefore, may well act as a buffer, or
resistance factor, in the stress/illness connection.
The hardiness trait would affect an individual's
perception of chemotherapy, thereby resulting in a
greater resistance to the symptomatology of anticipatory
nausea and vomiting that evolves from the stressor
chemotherapy.
Existential psychology provides the basic framework
for the development of the concept of hardiness as it is
used in this study.

Existential philosophy views the
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ultimate aim of life as the "creation of personal
meaning through decision making and action in the
continual pursuit of possibility" (Bigbee, 1985, p. 54).
The existential viewpoint (Bigbee, 1985) considers
stressful life events as a challenge that enables an
individual to grow and pursue a higher level of
authenticity.
From this overview of existential philosophy, the
three basic components of the hardiness characteristic
evolve (Kobasa, 1979).

These three components are

identified as control, commitment, and challenge.
Control is determined according to the individual's
locus of control:

internal or external.

Internally

oriented people are able to face stressors by believing
they can modify the stressor as a result of their own
efforts or attributes, while externally oriented people
believe they have little to no control over events in
their lives.
of control.

Hardy individuals have an internal locus
Commitment is identified in the hardy

individual as a purpose in life which is supported by a
strong sense of dedication to personal values, beliefs,
and to self.

Committed individuals have a belief system

that acts to decrease the perception of life events as
threatening.

Lastly, challenge is perceived by the

hardy person as an opportunity for growth (Kobasa,
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1979) .

Stress and change are therefore viewed as

potential growth experiences.
Definition of Terms
The key concepts identified for this study were:
A.

Hardiness:

a specific personality characteristic

which acts as a resistance factor in the stressillness connection.

The hardiness characteristic is

a composite of three other traits identified as
control, commitment, and challenge (Kobasa, 1979).
B.

Control:

the belief that one can influence or

direct the events in their life (Kobasa, 1979).
C.

Commitment:

the ability to believe in the

importance of and feel deeply involved in the
activities of one's life (Kobasa, 1979).
D.

Challenge;

the belief that change is a normal part

of life and an incentive for growth rather than a
threat to growth (Kobasa, 1979).
E.

Perception:

the process of evaluating stimuli

as threatening or nonthreatening.
F.

Anticipatory nausea:

the patient's perception of

feeling sickness at the stomach that occurs twentyfour hours prior to, in expectation of, chemotherapy.
G.

Anticipatory vomiting:

the patient's perception of

the expulsion of stomach contents (emesis) that
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occurs twenty-four hours prior to, in expectation
o f , chemotherapy.
H.

Chemotherapy:

the use of chemical pharmacologic

agents in the treatment of cancer.
As a result of examining anticipatory nausea and
vomiting as symptoms resulting within the stress and
illness framework, factors which mediate this response
must be examined.

Therefore, the following research

question was posed:

What is the relationship of the

hardiness characteristic to anticipatory nausea and
vomiting experienced by the patient receiving cisplatin
chemotherapy?
The conceptual framework of the research question
is diagramed below (see Figure 1):
rControl
Hardiness—4 Commitment
I _ '-Challenge

I
I

I

-N.

Stressor--------- Perception--------- Anticipatory Nausea
(Chemotherapy)
and Vomiting
Figure 1. Model of Conceptual Framework
Hypothesis
The resultant hypothesis was identified as:
Individuals with a high level of the hardiness
characteristic (control, commitment, and challenge) will
experience less anticipatory nausea and/or vomiting than
21

those individuals with a low level of the hardiness
characteristic.
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CHAPTER THREE
Methodology
Research Design
The purpose of this study was to describe the
relationship between the hardiness characteristic and
anticipatory nausea and vomiting experienced by patients
receiving chemotherapy.

A prospective descriptive

correlational design was used.
Sample and Setting
The source of subjects for this study was oncology
patients who received chemotherapy on an in-patient basis
at a 529-bed metropolitan regional hospital, a 190-bed
community hospital, a 350-bed regional hospital, and a
405-bed regional hospital, all of which were located in
the Midwest.

A convenience sample of 40 subjects was

utilized for this study.

The sample consisted of men and

women with a confirmed diagnosis of cancer.

The subjects

all received cisplatin, at least 70 mg/m2, as one of their
primary chemotherapeutic agents.

The subjects were

between cycle two and six of their chemotherapy protocol.
In addition, the subjects were between the ages of 18-79,
alert and oriented to person, place, and time, and able to
read and write English.
23

Patients were excluded from this study if they had
a confirmed primary gastrointestinal cancer or were
receiving radiation therapy to the upper and lower
abdomen.
Instruments
There were two major instruments for data
collection used in this study:

the Health Related

Hardiness Scale (HRHS) and the Rhodes Index of Nausea
and Vomiting Form 2 (INV Form 2).

In addition, a

demographic and related data form was utilized to
obtain information about the subjects via interview
(Appendix A ) , a chart review form was utilized to
obtain information relevant to the chemotherapy protocols
the patient had received and was to receive (Appendix
B), and a patient questionnaire was utilized to obtain
information about how the patient felt after
chemotherapy (Appendix C).
In early studies aimed at measuring the hardiness
characteristic, Kobasa's Hardiness Scale (Kobasa, 1979)
was widely used.

The Health Related Hardiness Scale

(Pollock, 1986) is a more recent instrument developed to
better measure the hardiness characteristic in
individuals with an actual or potential health problem
(Appendix D).

The HRHS contains 40 items rated on a 6-

point, forced-point scale from strongly disagree to
24

strongly agree.

There are three subscales for

control, commitment, and challenge.

The 14 items to

measure control were selected from the Multidimentional
Health Locus of Control Scale, while items to measure
the commitment and challenge concepts were developed
from operational definitions of commitment to health
related activities and motivation for health promotion.
Content validity of the HRHS was addressed by
Pollock (1989) by asking a panel of judges (faculty and
doctoral students with experience in adult health) to
evaluate the representativeness of the control,
commitment, and challenge items.

Interrater reliability

was .85 via interclass correlation of raters, thus
assuring selection of the best items to measure the
three concepts.

This same panel evaluated both the HRHS

and Kobasa's Hardiness Scale (Kobasa, 1979) for
measuring the hardiness characteristic, with experts all
agreeing that the HRHS was the more appropriate
instrument (Pollock, 1989).
Internal consistency of the HRHS was established
via a pilot study (N=65 well adults) in which the
subjects completed both Kobasa's Hardiness Scale and the
HRHS.

The HRHS indicated better reliability (higher

alpha coefficients) as compared to Kobasa's scale.
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Table 1 below illustrates the alpha coefficients obtained
from each test.
Table 1
Comparison of Alpha Coefficients from HRHS and Kobasa's
Hardiness Scale
Total instrument;
Control subscale:
Commitment subscale:
Challenge subscale:

HRHS
.80
.82
.74
.65

Kobasa's Scale
.65
.55
.58
.23

Internal consistency reliabilities using Cronbach's
alpha for the 40-item HRHS for this study were .70 for the
total score, .65 for the control subscale,

.48 for the

commitment subscale, and .26 for the challenge subscale.
The Rhodes Index of Nausea and Vomiting Fomn 2
(Rhodes, Watson, Johnson, Madsen, & Beck, 1987) was
utilized to measure anticipatory nausea and vomiting.
The INV Form 2 is an 8-item, 5-point, Likert-type scale,
utilized in a self-report method (Appendix D) .

The INV

Form 2 was designed to measure nausea and vomiting in the
subject in 12 hour blocks of time after the subject had
received chemotherapy.

For the purpose of this study, the

time blocks were changed to 24 hours.

The tool was

adapted with permission of the author.
Form 2 was developed to measure the subject's
perceived frequency of nausea, duration of nausea,
distress from nausea, frequency of vomiting, amount of
vomiting, distress from vomiting, frequency of dry heaves.
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and distress from dry heaves.

The subject's total symptom

experience score is obtained from the total score on the
INV Form 2.

In addition, there are several sub-scores

that can be derived from the INV Form 2.
Rhodes et al.

(1987) estimated concurrent validity

of the INV Form 2 by comparing the ratings of patients
with the ratings of a family member the evening after
the patient received chemotherapy, using Spearman's
correlation coefficient (r=.B7, n=18, p=.001).
Construct validity was measured by the tool's ability to
discriminate between cancer patients and well citizens.
The Wilcoxon-Mann Whitney test was used for this purpose.
Through factor analysis the three experience scales were
supported as being distinct and unique.
After the completion of a study of nausea and
vomiting using a previously constructed Index of Nausea
and Vomiting Form 1 (INV Form 1) the INV Form 2 was
developed.

Internal reliability of the INV was measured

by two methods.

The split-half correlation was .90, and

Cronbach's Alpha was .89 to .97 over 12 index
administrations.

These findings relate to the INV Form 1.

No other information specific for Form 2 was given except
Cronbach's Alpha, which was .98

(Rhodes et al., 1987).

The coefficient alpha for the twelve INV Form 2 items
for this study was .93.

The coefficient alpha for the
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nausea experience subscale was .92, .95 for the vomiting
experience subscale, and .92 for the retching experience
subscale.
Procedure
Application was made to the Grand Valley State
University Human Research Review Committee for proposal
approval.

Approval was also obtained from the

Research Committees of the hospitals in which subject
recruitment took place.

Once approval from all

agencies was obtained, subject recruitment and data
collection proceeded.
Recruitment of subjects occurred on the oncology
units within three of the identified hospitals and via an
oncology physician's office for patients admitted to the
remaining hospital.

An oncology nurse was contacted in

three of the institutions and upon thorough discussion of
the research data collection process, was recruited to
collect data for the study.

Each data collector was

provided the appropriate tools, consent forms, and paper
products required for data collection.

Identification of

subjects who met basic eligibility criteria occurred
on a daily (Monday through Friday) basis at each
institution.

The researcher or nurse data collector

reviewed admitting orders to confirm that the subject was
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indeed receiving cisplatin and was between cycle two and
six of treatment.
Once eligible subjects had been identified, the
researcher or nurse data collector made personal contact
with each subject.

The researcher or nurse data collector

introduced herself, gave a brief statement regarding the
nature of the research (Appendix F) , and presented the
subject with the appropriate consent form (Appendix G ) .
Explanations were given at this time regarding the process
for data collection.

The researcher or nurse data

collector then gave the subject time to read the
consent form privately and then returned to the room to
answer any questions and to pick up the consent form if
it was signed.

Once consent was obtained, one copy of the

consent was placed in the subject's chart, one copy
given to the subject, and the final copy retained by the
researcher.

At this time, the researcher or nurse data

collector interviewed the subject, utilizing the
demographic and related data form (Appendix A ) .

The

researcher or nurse data collector then completed the
chart review form (Appendix B).
The patient questionnaire and the Health Related
Hardiness Scale (Pollock, 1987) were mailed to the
subjects approximately 10 days after the present
chemotherapy treatment, requesting that they complete the
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forms and mail them back to the researcher (Appendix H ) .
The intent was to have the subjects complete the
questionnaires at a point in time when they had
recovered optimally from the previous chemotherapy
treatment and were not yet experiencing any distress in
anticipation of the next treatment.

Subjects were to

complete the HRHS and the patient questionnaire within the
privacy of their own home.

Subjects were requested to

mail the forms back to the researcher in a stamped,
addressed envelope that was provided.

To enhance

confidentiality, the questionnaire was coded by number
and the subjects were instructed not to identify
themselves on any of the questionnaires completed during
this study.

If the forms were not received by the

investigator within ten days of being mailed to the
subject, a follow-up phone call was placed to the
subj ect.
The INV Form 2 (Rhodes et al., 1987) was
administered by the researcher or the nurse data collector
the first day of the next admission to the hospital for
chemotherapy, prior to pre-medications or chemotherapy
being initiated.

The subject was asked to complete the

INV Form 2 at this time.

The questionnaire was then

placed in a plain envelope and returned to the researcher
(Figure 2).
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Identify subjects
Obtain consent
Administer Demographic
and Related Information
Questionnaire
Complete Chart Review Form

Day of admission
for chemotherapy
(Course 2, 3, 4, or 5)

Mail Cover Letter,
Patient Questionnaire,
and HRHS to subject

Day 10
Post-chemotherapy

Subject completes
Patient Questionnaire &
HRHS and mails back to
the researcher
Day 11-16
post-chemotherapy

w
H

Figure 2.

Time Line of Interaction With Subjects

Follow-up call
if forms not
received by
researcher
Day 16-20
Post-chemotherapy

Admission of subject
for next chemotherapy
(Course 3, 4, 5, or 6)
Administer IHV Form 2
Day 20-31
Post-chemotherapy

If requested at the time of informed consent,
results of the study were mailed to the subject at
the completion of the study.

All consent forms and

returned forms were kept in a locked file at the
researcher's home to enhance confidentiality.
The chance of untoward effects resulting from this
study were considered minimal, however, two potential
risks were identified.

First, it was possible that the

subjects could become fatigued when completing the 40-item
Health Related Hardiness Scale.

The researcher attempted

to reduce this risk by enabling the subjects to take this
paper and pencil test in their own home, allowing the
subjects to rest as needed.
Second, the study deals with the psychophysiological
phenomenon of anticipatory nausea and vomiting.

It was

possible that through too much information being given to
patients who have never experienced anticipatory nausea
and vomiting, they were at an increased risk of developing
anticipatory nausea and vomiting during their chemotherapy
protocol.

In an effort to reduce this threat, the

researcher and nurse data collectors did not expose the
subjects to the words "anticipatory nausea and vomiting".
Finally, the tool utilized to measure this phenomenon
was identified simply as a means to measure the subject's
personal experience before chemotherapy.
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CHAPTER FOUR
Data Analysis
The life stress and illness model (Rahe, 1988)
supports the relationship between stressor and symptom
development in the cancer patient receiving chemotherapy.
Anticipatory nausea and vomiting may be a
psychophysiologic response to chemotherapy.

The

literature identifies the hardiness characteristic as a
buffer, or resistance factor, in the stress/illness
connection.

Therefore, it is important to explore the

relationship between hardiness and anticipatory nausea and
vomiting in cancer patients.
The independent variable, the hardiness
characteristic, including the concepts control,
commitment, and challenge, were measured at the interval
level for the total score.

The dependent variable,

anticipatory nausea and vomiting experienced by the
patient receiving cisplatin chemotherapy, was also
measured at the interval level.

The Pearson r correlation

coefficient was used to test the hypothesis:

Individuals

with a high level of the hardiness characteristic
(control, commitment, and challenge) will experience less
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anticipatory nausea and/or vomiting than those individuals
with a low level of the hardiness characteristic.
Relationships were considered to be significant at the
0.05 level.
One other relationship explored by the study was the
differences between males and females in relation to the
hardiness characteristic in each group.

The t-test was

used to determine if the gender groups differed
significantly in relation to the hardiness characteristic.
All data were analyzed using the SPSS/PC package.
Characteristics of Subjects
Identification of potential subjects for the study
was made by the principal researcher and oncology nurse
data collectors over a two year period within four
institutions.

More than one hundred patients were

screened as potential candidates for the study, however,
only forty subjects met the inclusion and exclusion
criteria and consented to participate in the study.

All

forty candidates completed portions of the data collection
process, with twenty-nine subjects completing all
components of the data collection process.

Nine subjects

were unable to complete data collection as their treatment
regime was changed prior to completing the final data
collection tool, e.g., chemotherapy changed to radiation
therapy or chemotherapy placed on hold.
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One subject was

unable to complete the data collection instruments at home
due to existing family dynamics which prevented him from
receiving the mail.

One subject expired as a result of

his cancer just prior to readmission for chemotherapy,
thus the final data collection tool was not completed.
The breakdown of subjects in the study according to
study site is shown in Table 2.
Table 2.
Distribution of Sample Based on Data Collection Site
# of Subjects

Site
529 bed regional hospital

29

190 bed community hospital

6

350 bed regional hospital

5

405 bed regional hospital

0

Twenty-four of the subjects were male and sixteen of
the subjects were female.

Age of the participants ranged

from 36 to 79 years of age.

The mean age was 56.87, with

a standard deviation of 10.16.

Thirty-two of the

participants were married, four subjects were single,
divorced, or widowed and living alone, and four subjects
were single divorced, or widowed and living with someone.
Thirty-nine subjects identified themselves as Caucasian,
one subject as Hispanic.

The distribution of subjects by

ethnicity is listed in Table 3.
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The distribution of

subjects by education is listed in Table 4.

Demographic

characteristics were similar with respect to marital
status, race, and education.

The majority of subjects

were Caucasian and married with a high school or partial
college education.
Table 3
Distribution of Sample by Ethnicity
Group
Characteristic

Frequency

Percent

Dutch

8

20.0

Irish

5

12.5

German

13

32.5

Polish

2

5.0

Scottish

2

5.0

Mexican

1

2.5

English

2

5.0

Lithuanian

1

2.5

Native American Indian

2

5.0

Other

2

5.0

None

2

5.0

40

100.0

Total

36

Table 4.
Distribution of Sample by Education
Group
Frequency

Characteristic
Less than High School

Percent

6

15.0

High School

13

32.5

Partial College

14

35.0

College

4

10.0

Beyond 4 Years of College

3

7.5

40

100.0

Total

All 40 subjects had a confirmed diagnosis of cancer.
Twenty subjects were diagnosed with lung cancer, while the
remaining subjects had one of a variety of primary sites
(Table 5).

Twenty-six, or 65% of the sample had some

metastatic disease present.
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Table 5
Distribution of Sample Based on Primary Site of Cancer
Group
Frequency

Primary Site

Percent

Bladder

1

2.5

Testicle

4

10.0

Head/Neck

1

2.5

20

50.0

Breast

1

2.5

Bone

1

2.5

Uterine

2

5.0

Unknown

2

5.0

Other

7

17.5

N/A

1

2.5

40

100.0

Lung

Total

Point of entry into the study was after the
completion of at least one course of chemotherapy and
before receiving the fifth course of chemotherapy.
Twenty-seven subjects were entered into the study prior to
their second course of chemotherapy, eight subjects prior
to their third course, four subjects prior to their fourth
course, and one subject was entered prior to his fifth
course of chemotherapy.

The minimum dose of cisplatin the
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subject could receive for inclusion into the study was
70 iag/m2.

The distribution of the subjects based on

cisplatin dose is listed on Table 6.

Twenty-three

subjects, or 57.5% of the sample received their cisplatin
dose split and administered over more than one day, while
the remaining 17 subjects, or 42.5% of the sample,
received their cisplatin in a single dose.

While

cisplatin was identified as the primary chemotherapeutic
agent the subjects were to receive, all forty subjects
received at least one additional chemotherapeutic agent
during their treatment regime.
Table 6
Distribution of Sample Based on Dose of Cisplatin
Group
Dose Range

Frequency

Percent

7 0 - 7 9 mg/m2

17

42.5

80 - 89 mg/m2

8

20.0

9 0 - 9 9 mg/m2

6

15.0

100 - 109 mg/m2

8

20.0

> 120 mg/m2

1

2.5

40

100.0

Total

Fifteen of the subjects had someone close to
them receive chemotherapy in the past.
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Seven of the

individuals identified as being close to the subjects had
experienced distressing symptoms while receiving
chemotherapy, with nausea being the distressing symptom in
four of the cases.

Eight of the 40 subjects had

themselves received chemotherapy treatments in the past
(prior to the present regime), with six of those
individuals having experienced distressing symptoms during
that treatment regime.

Nausea was identified as the most

frequent distressing symptom in that group, experienced by
three of the six subjects.

Three subjects experienced

nausea and/or vomiting prior to the initial chemotherapy
treatment of the present treatment regime.

Three subjects

experienced mild distress from nausea in the two days
prior to the chemotherapy treatment at which they were
recruited into the study.

No one experienced any vomiting

in the two days prior to the chemotherapy treatment at
which they were recruited into the study.
Table 7 identifies the distress from nausea
experienced one week after the previous chemotherapy
treatment as reported by the subjects.

Table 8

identifies the distress from vomiting experienced one week
after the subject's previous chemotherapy treatment as
reported by the subjects.

It is evident that of those

subjects experiencing nausea, mild nausea was most
frequently experienced.

Post-chemotherapy vomiting was
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experienced by fewer of the subjects than nausea, but was
most often described as causing moderate distress.
Pharmacological intervention to control post-chemotherapy
nausea and vomiting was utilized by 77.9% of the subjects
reporting this information (Table 9).

Of the drugs

identified, lorazepam (Ativan), prochlorperazine
(Compazine), metoclopramide hydrochloride (Raglan),
trimethobenzamide hydrochloride (Tigan), thiethylperazine
maleate (Torecan), and ondansetron hydrochloride (Zofran),
Torecan was taken by 50% of the subjects for control of
post-chemotherapy nausea and vomiting.
Table 7
Distribution of Sample by Nausea Experienced One Week
After Chemotherapy (n=36).
Group
Frequency

Valid Percent

No nausea

11

30.6

Mild distress

13

36.1

Moderate distress

8

22.2

Severe distress

4

11.1

36

100.0

Characteristic

Total

41

Table 8.
Distribution of Sample by Vomiting Experienced One Week
After Chemotherapy

(n=36).
Group
Frequency

Valid Percent

21

58.3

Mild vomiting

7

19.4

Moderate vomiting

8

22.2

Severe vomiting

0

0.0

36

100.0

Characteristic
No yomiting

Total
Table 9.

Distribution of Sample by Freauencv of Medication Taken
for Nausea & Vomiting One Week After Chemotherapy fn=36).
Group
Frequency

Valid Percent

8

22.2

2 X in 24 hours

15

41.7

3 - 4 X in 24 hours

11

30.6

2

5.6

36

100.0

Characteristic
No medication

> than 4 X in 24 hours
Total
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Thirty-nine of the forty subjects received Zofran
prior to the administration of cisplatin, thirty received
dexamethasone (Decadron), and seventeen received Ativan.
Two subjects received furosemide (Lasix) as part of the
pre-chemotherapy regime and one subj ect received
diphenhydramine hydrochloride (Benadryl).

All but two

subjects received a combination of two or more drugs prior
to the administration of cisplatin.

The two subjects

receiving only one drug prior to the administration of
cisplatin received Zofran intravenously.
Thirty-six of the forty subjects were administered
the Health Related Hardiness Scale (HRHS).
HRHS forms had one or more missing items.

Six returned
Scores have the

potential to range from 40-240, with low scores indicating
hardiness.

Hardiness is determined by using the median

split of the sample, with those scores below the median
indicating the presence of hardiness.

Subscores for each

of the concepts control, commitment, and challenge can be
obtained from the HRHS.

Control scores range from 14-84

with low scores indicating high control, commitment scores
range from 13-78, with low scores indicating high
commitment, and challenge scores range from 13-78, with
low scores indicating high challenge.

The mean scores,

median scores, and the standard deviations for the HRHS
and the subscales are shown in Table 10.
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With a median

score of below 90 representing hardiness, 14 subjects, or
46.7% scored below the median score to indicate
hardiness.

Seventeen subjects, or 50.0% of the 34

subjects completing the control subscale scored below the
median score of 41.50 for the subscale indicating control.
Twelve subjects, or 37.5% of the thirty-two subjects
completing the commitment subscale scored below the median
score of 23 indicating commitment.

Sixteen, or 47.1% of

the total thirty-four subjects completing the challenge
subscale scored below the median score of 2 4 indicating a
sense of challenge.
Table 10.
Mean Scores of the HRHS and Subscales
Score
Scale/Subscales

M

Median

SD

HRHS Total (n=30)

87.833

90.00

14.518

Control (n=34)

41.971

41.50

9.622

Commitment (n=32)

23.375

23.00

6.729

Challenge (n=34)

25.618

24.00

6.325

Twenty-nine subjects were administered the Rhodes
Index of Nausea and Vomiting Form 2 (INV Form 2).

As this

was the final data collection tool administered, eleven
subjects were unable to complete this form (see page 36).
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Two forms had missing data when returned.

The INV Form 2

has a potential range in scores from a low

of 0to a

maximum of 32.

In addition, scores can be obtained

from a variety of subscales.

The subscales examined are

those identified within the symptom experience subscale.
They include the nausea experience with a potential range
of scores of 0-12, the vomiting experience with a
potential range of scores of 0-12, and the retching
experience with a potential range of scores of 0-8.

The

mean score and standard deviations for the INV Form 2
total and selected subscales are shown on table 11.

These

scores reflect very low levels of perceived anticipatory
nausea, vomiting, or retching in the subject group as a
whole.
Table 11
Mean Scores for the INV Form 2 and Selected Subscales
Score
Scale/Subscales

M

INV Form 2 total (n=27)

SD

1.667

3.637

1.179

2.144

Vomiting experience (n=29)

.241

.912

Retching experience (n=28)

.179

.670

Nausea experience (n=28)
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Analysis of the Research Hypothesis
The Pearson r correlation coefficient was used to
test the study hypothesis;

Indiyiduals with a high leyel

of the hardiness characteristic (control, commitment, and
challenge) will experience less anticipatory nausea and/or
yomiting than those indiyiduals with a low leyel of the
hardiness characteristic.

The Pearson r correlation

coefficients were calculated to determine if a significant
relationship existed between the total HRHS score with the
total INV Form 2 score.

Mean substitution with the

yariable mean was used for those few items not answered by
the participants.

Results indicated no significant

relationship between the total HRHS and the total INV
Form 2 (r=.07, p=.72), thus the hypothesis was not
supported.
A t-test was utilized to examine the differences
between males and females in relation to the hardiness
characteristic in each group.

There was homogeneity of

yariance so the pooled formula was used.

There was no

difference in the HRHS total based on gender (t=.77,
dF=32, p=.445).
The Pearson r correlation coefficient was used to
test each of the HRHS subscales (control, commitment, and
challenge) to determine if a significant relationship
existed between a subscale and the INV Form 2 score.
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Results indicated no significant relationship between any
of the subscales and the INV Form 2 total (Table 12).
Table 12
Correlations Between HRHS Subscales and INV Form 2 Totals
Subscales

Coefficients

Control
Commitment
Challenge

Significance

.19

.35

-.19

.40

.10

.64

p=<.05
Additional Findings of Interest
Ethnicity and its relationship to hardiness was
explored.

A t-test was used to examine the differences

between Dutch/German and Irish ethnic groups in relation
to the HRHS total.

These groups were chosen as they were

the largest ethnic groups identified within the sample.
There was no difference in the HRHS total based on
ethnicity (t=.28, dF=4.38, p=.791).
A variety of relationships were examined related to
the development of anticipatory nausea and vomiting.

A t-

test was used to examine the differences between subjects
who had and those who had not received chemotherapy in the
past in relation to the anticipatory nausea experience
(subscale of the INV Form 2) with the present treatment
protocol.

There was no difference in the anticipatory

47

nausea experience based on past chemotherapy experience
(t=-.44, dF=26, p=.665).
The anticipatory nausea and vomiting experience was
also examined in relationship to subjects having had
someone close to them receive chemotherapy in the past.

A

t-test was used to examine the differences between
subjects who had someone and those who did not have
someone close to them receive chemotherapy in the past in
relation to the anticipatory nausea experience and the
anticipatory vomiting experience with this chemotherapy
regime.

There was no difference in the anticipatory

nausea experience based on having had someone close
receive chemotherapy (t=1.02, dF=2 6, p=.318) nor in the
anticipatory vomiting experience based on having had
someone close receive chemotherapy (t=.63, dF=9.87,
p=.544).
The Pearson r correlation coefficient was used to
determine if a significant relationship existed between
the amount of nausea one week after chemotherapy (from the
previous course of cisplatin) with the amount of
anticipatory nausea for the present course of
chemotherapy.

The Pearson r indicates there is some

relationship approaching significance (r=.33, p=.07).
This same relationship was explored substituting vomiting
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for nausea, with the results indicating significance
(r=.46, p=.01).
The dose of cisplatin and the method of administering
the cisplatin (single dose or split doses) were analyzed
in relationship to anticipatory nausea and vomiting.

The

Pearson r correlation coefficient was used to determine if
a significant relationship existed between the dose of
cisplatin administered and the anticipatory nausea
experience.

Results indicated no significant relationship

between the dose of cisplatin and anticipatory nausea (r=.05, p=.80).

Similarly, there was no significant

relationship between the dose of cisplatin and
anticipatory vomiting (r=-.27, p=.14).

A t-test was

utilized to examine the differences between groups based
on the dosing of cisplatin (single dose or split doses)
and the amount of anticipatory nausea experienced by
subjects.

There was no significant difference between the

single dose group and the split dose group and the amount
of anticipatory nausea experienced (t=2.02, dF=13.21,
p=.064).
Lastly, the Fisher's Exact test was used to analyze
subjects who scored less than 90 on the HRHS (indicating
hardiness) and subjects who scored 90 or greater on the
HRHS with subjects who experienced no anticipatory nausea
and vomiting and subjects who experienced some degree of
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anticipatory nausea and vomiting (based on INV Form 2
totals).

Table 13 demonstrates this relationship.

Table 13
Relationship Between Presence of Hardiness and
Anticipatory Nausea and Vomiting
Anticipatory Nausea and Vomiting
No
Hardy (n=13)
Not Hardy (n=14)

Yes

10

(77%)

3 (23%)

8

(57%)

6 (43%)

p=.249, one-tailed.
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CHAPTER FIVE
Discussion and Implications
Discussion
This study was designed to examine the relationship
between personality hardiness and the experience of
anticipatory nausea and vomiting within a sample of
patients receiving cisplatin as their primary
chemotherapeutic agent.

Kobasa (1979) identified

hardiness as a buffer or resistance factor in the
stress/illness connection.

Recognizing that the symptoms

of anticipatory nausea and vomiting may evolve via the
process described in the life stress and illness model
(Rahe, 1988), the results of this study were expected to
support a correlation between hardiness and anticipatory
nausea and vomiting.
this premise.

The data, however, did not support

The findings of the study revealed no

statistically significant relationship between hardiness
and anticipatory nausea and vomiting.

It is of clinical

importance, however, that a much lower percentage of hardy
individuals experienced anticipatory nausea and vomiting
than the non hardy group.
The mean scores for the INV Form 2 and selected
subscales (Table 11) indicate very low levels of perceived

51

nausea, vomiting, or retching in the tventy-fcur hours
prior to admission for chemotherapy.

It was anticipated

that there would be greater variability in the degree of
these symptoms within the subject group as a whole.

There

may be a number of factors which influenced these low
scores.
The literature (Pratt, Lazar, Penman, & Holland,
1984) supports the development of anticipatory nausea and
vomiting based on the classical conditioning model, from
which repeated experiences with an unconditioned stimulus
(chemotherapy) contributes to an unconditioned reflexive
response (post-chemotherapy nausea and vomiting).

With

repeated experiences, the conditioned response
(anticipatory nausea and vomiting) may evolve.

This model

is supported by Morrow (1984) , identifying that paLicr.ts
who experience moderate, severe, or intolerable nausea and
vomiting post-chemotherapy were more likely to experience
anticipatory nausea and vomiting.

Data in this study

found a relationship approaching significance between the
amount of nausea one week after chemotherapy (from the
previous course of cisplatin) with the amount of
anticipatory nausea and vomiting for the present course of
chemotherapy.

Significance was achieved in examining this

same relationship substituting vomiting for nausea.
findings support the literature, indicating post-
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These

chemotherapy nausea and vomiting influence the development
of anticipatory nausea and vomiting.
Based on the classical conditioning model, it is
logical that the further into the treatment protocol, the
greater the potential would exist for anticipatory nausea
and vomiting to develop.

This is particularly true if the

patient experiences distressing stimuli which act to
elicit an unconditioned reflexive response.

While the

discussion above explains that the majority of subjects
experienced no to mild levels of distress related to post
chemotherapy nausea and vomiting, this may be due, in
part, to the fact that 27 subjects were entered into the
study prior to their second course of chemotherapy.

The

majority of subjects had few experiences with chemotherapy
at this point, thus this may have contributed to the low
INV Form 2 scores.
The introduction of ondansetron (Zofran), a serotonin
antagonist, may also have influenced the INV Form 2 and
subscale scores.

Zofran was introduced to the clinical

setting during the period of time the study was designed.
Zofran has been widely utilized since that time as an
antiemetic in pre-chemotherapy treatment regimes, as
evidenced by the fact that 39 out of the 40 subjects in
this study received this drug as a premedication for
cisplatin.

Clinical trials with this drug had promised
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new advances in the control of chemotherapy-induced nausea
and vomiting (Egan, Taggart, & Bender, 1992).

Control of

nausea and vomiting during and immediately after
chemotherapy will influence the development of
anticipatory nausea and vomiting (Goodman, 1987).

While

no direct analysis of Zofran, post-chemotherapy nausea and
vomiting, and anticipatory nausea and vomiting was carried
out in this study, the low INV Form 2 and subscale scores
may be a reflection of the effectiveness of this drug in
controlling post-chemotherapy nausea and vomiting.
Additional factors thought to influence the
development of anticipatory nausea and vomiting were
examined.

The theoretical framework for this study

recognizes that many factors interface to produce an
individual's perception and response to a stressor.
Included in these factors are the life events an
individual experiences.

Experiences identified in the

study which would be considered life events include having
had someone close to the subject receive chemotherapy in
the past and the subject himself having received
chemotherapy prior to the current treatment regime.
There was no difference in the anticipatory nausea and
vomiting experience based on either of these life events.
This may be attributed to the fact that only 15 subjects
had someone close to them receive chemotherapy and only
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in seven of these instances was the person perceived as
having distressing symptoms as a result of the
chemotherapy, of which nausea was the distressing symptom
identified in four of the cases.

Only eight of the 40

subjects had received chemotherapy treatments previously,
six of which experienced distressing symptoms, and three
of these six had experienced nausea as the distressing
symptom.

It may be possible that other factors are

impacting the perception of chemotherapy, both on an
individual and societal level.

Education has improved

both on an individual level and family level for those
undergoing chemotherapy treatments.

Information has been

widely disseminated within the public sector related to
cancer, its treatment, potential side effects resulting
from treatment, and the increasing frequency of positive
outcomes once diagnosed with cancer.
survivorship and all that it implies

In addition,
has become the focus

of much of the information released to the health care
team and public today.

Based on this, the perception of

cancer and its treatment may be slowly changing

and may be

perceived in a less negative light.
The literature does not explore in detail factors that
affect the development or presence of hardiness.

In an

effort to further explore this, two additional
relationships were examined.
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The first relationship

examined was that of hardiness and gender.

The findings

of this study indicated that there was no difference in
the HRHS total score based on gender.

Gender

identification is influenced by biological aspects (e.g.,
anatomic and physiologic organs, hormones, etc.),
psychologic aspects (e.g., sexual self-concept), and
sociocultural aspects (e.g., gender role learned through
family and society)

(Hogan, 1985).

It is plausible that

these biopsychosocial factors may impact the development
of hardiness, recognized in the literature as a
personality characteristic, although this study did not
support that relationship.
Lastly, ethnicity and its relationship to hardiness
was explored.

If factors can be identified that influence

the development and presence of hardiness, ethnicity may
be one of those factors.

Subjects were asked to identify

the ethnic group that they most closely identified with in
their own lives.

The Dutch and German groups were joined

for analysis as they have somewhat similar cultural norms.
The Dutch/German and Irish groups were chosen to examine
the differences between them as they were the largest
ethnic groups identified within the sample.

The findings

did not identify a difference in the HRHS total based on
ethnicity.
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Limitations
As with many studies, there were identified threats
to both internal and external validity.

There were two

major threats to internal validity identified in this
study:

maturation and testing effects.

It was possible

for the subjects in this study to experience the effect of
maturation as a result of their cancer disease process.
Often fatigue and disease progression are unavoidable due
in part to the chemotherapy treatment and the disease
trajectory itself.

Attempts were made to control this

process by expediting the data collection process.

Only a

four week interval occurred between the initial contact
and the final questionnaire.
The second risk to internal validity, testing
effects, may have occurred as a result of the nature of
the questionnaires.

If the subjects were exposed to the

questionnaire dealing with the hardiness characteristic
prior to their next chemotherapy treatment, this may have
stimulated the subjects to examine their own attitudes
toward life and their diagnosis.

This may, in turn, have

affected their normal response to chemotherapy and altered
the research findings.

No mention of hardiness, control,

commitment, or challenge was made directly to the
subjects.

They were told that this study was to examine

how people view certain issues related to their own
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health.

In addition, the questionnaires were administered

at one point between cycle two and six of the individual's
chemotherapy protocol, thus the pattern of anticipatory
nausea and vomiting would likely be already established.
The two major threats to generalizability were
identified as experimenter effects and characteristics of
the sample.

The performance of the subjects may have been

affected by the researcher's expectations.

The subjects

may have recognized the researcher's interest and
enthusiasm for the project, and answered the
questionnaires in the manner they think the researcher or
nurse data collectors expected them to be answered.

An

attempt was made to reduce this threat by the presentation
of a brief, simple introductory statement made to each
subject (Appendix F ) .
The small sample size was a limitation to the study.
The subjects were fairly homogenous as a group with the
majority being married, Caucasian with a high school or
partial college education.

Another limitation was that

convenience sampling was utilized for the study.

Almost

every patient receiving cisplatin during the study period
was reviewed as a potential subject for the study,
excluding only those who did not meet the inclusion and
exclusion criteria.

Despite this, data collection took

two years with four data collectors in four different
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institutions.

This was attributed, in part, to the fact

that cancer therapy advances, making other
chemotherapeutic drugs available to patients, occurred
during the time frame this study was conducted.

Several

subjects consented to participate in the study, but were
unable to complete all aspects of the data collection
process as a result of a change in therapy.

One subject

expired as a result of his cancer prior to completing the
data collection process.

As a result of this method of

sampling, the findings cannot be generalized to the total
cancer population.
Another factor that may have influenced the results
of this study was the introduction of Zofran as an
antiemetic.

This drug has been identified in the

literature and by cancer clinicians as effectively
reducing the amount of post-chemotherapy nausea and
vomiting.

The effect of this drug on the study results is

unknown, but may have impacted the levels of anticipatory
nausea and vomiting experienced by the subjects.
The Health Related Hardiness Scale used in this study
must be examined as a potential limitation related to the
results of this study.

The reliability coefficients for

the challenge subscale (.26) and the commitment subscale
(.48) indicate a low degree of internal consistency within
these scales.

Wagnild and Young (1991) examined a number
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of concerns in relationship to the instruments presently
being used to measure hardiness.

Their review of the

literature revealed that a number of studies have
identified the challenge subscale as being problematic and
lacking internal consistency.

Hull, Van Treuren, and

Virnelli (1987) also examined hardiness and its
subcomponents, identifying that only commitment and
control have adequate psychometric properties (based on
the Hardiness Scale developed by Kobasa) and are
systematically related to health outcomes.

Hull, Van

Treuren, and Virnelli recommend that composite hardiness
should not be calculated because this does not allow for
the independent contributions of each subcomponent
(challenge, commitment, and control).

Pollock and Duffey

(1990) describe the development and the psychometric
evaluation of the present HRHS scale, which has evolved to
a 34-item instrument.

The conclusion of the authors is

that two separate but related dimensions exist, those of
commitment/challenge and control.

The recommendation is

that a total HRHS score and the two subscores be obtained
from this newer instrument.
At the time this study was designed, the 40-item HRHS
was the current instrument to measure hardiness and the
subcomponents control, challenge, commitment.

Further

analysis of the instrument has identified problems with
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measuring the three subcomponents individually.

Based on

the variety of instruments available to measure hardiness
and the questions that remain related to the consistency
of the subscales, further research and testing of the
instruments is indicated.
The data collection tool used to elicit information
related to post-chemotherapy nausea and vomiting (Appendix
C) was also a limitation to the study.
designed as a self-reporting tool.

This tool was

It was completed by

the subjects approximately two weeks after the previous
chemotherapy treatment, thus the subject's perceived
experiences at that point in time may have differed from
their actual experiences at the time they were having
post-chemotherapy nausea and vomiting.

The tool is

designed poorly in regard that the responses allow room
for individual interpretation.

The responses include

choices such as no nausea, mild distress from nausea,
moderate distress from nausea, etc.

Each individual may

interpret these responses differently based on their own
sense of what mild, moderate, and severe indicate.
Implications for Nursing Practice
While the hypothesis was not supported there remain
important implications for nursing practice.

Given the

fact that a much lower percentage of hardy individuals
experienced anticipatory nausea and vomiting when compared
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to non hardy individuals, recognition of hardiness in the
clinical setting is important.

Nursing interventions that

may impact an individual’s ability to maximize
characteristics such as hardiness in a stressful situation
may be as simple as giving the patient control over his
environment whenever possible.

These may be basic

interventions such as mutually establishing appropriate
medication schedules according to the patient's needs and
desires, empowering the patient to control environmental
stimuli such as noise, television, lights, and routines,
and advocating for the patient who chooses to use
interventions such as imagery and music therapy.

There

are undeniably many factors that impact the complexity
with which an individual responds to illness and the
treatment regime, however, hardiness may be an important
characteristic that may promote a positive response in the
patient facing stress and illness.
Cancer patients continue to provide a myriad of
challenges for nursing practitioners, particularly in
relationship to the side effects to chemotherapy.

This

study does support, albeit weakly, the relationship of
post-chemotherapy nausea and vomiting to anticipatory
nausea and vomiting.

While the scores of the INV Form 2

would indicate low levels of anticipatory nausea and
vomiting, it is important to control post-chemotherapy
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nausea and vomiting.

Clearly Zofran may impact this, but

it remains an important nursing challenge to provide
nursing care to combat the side effects of chemotherapy.
Such interventions may focus not only from a
pharmacological basis, but also from a behavioral basis.
These patients may benefit from interventions such as
imagery, music therapy, and relaxation breathing
techniques.
Recommendations for Future Research
Although the hypothesis was not supported
statistically, the fact that hardy individuals experienced
anticipatory nausea and vomiting in much lower percentages
would suggest a continued exploration with refined
instruments, additional variables and larger samples.
Based upon the changes encountered with cancer treatment
and symptom control since the inception of this study,
replication of this study would not be advised.

However,

as hardiness is considered a personality characteristic,
it could be examined in relationship to any health care
issue experienced by an individual.

This may include

symptom development, perceived symptom experience,
response to illness, impact on health promotion behaviors,
etc.
Hardiness should be explored not only in relationship
to health care issues, but in relationship to the
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characteristic itself.

Of particular interest would be

how this characteristic develops or evolves within the
individual.

If this were determined, recommendations

could be made for interventions to promote or develop the
characteristic within the individual or to enhance the
buffering effects of this characteristic in times of
stress or illness.
Another potential source for further research was
identified during the selection process of subjects for
this study.

Many of the potential subjects were not

receiving high dose cisplatin (>70mg/m2).

In one

location, fourteen potential subject charts were reviewed
with not one patient receiving high dose cisplatin,
despite the fact that the diagnosis may have indicated
this treatment regime was appropriate.

It is not the

intent of this study to determine appropriate medical
practice and this study did not examine the different
drugs used in conjunction with cisplatin, which may impact
the dose of cisplatin administered.

As a result of this

incidental finding, however, it may be of interest to
research factors influencing the dosing of cisplatin in
the various cancer patient populations and the
geographical locale of these patients.

64

Conclusion
The purpose of this study was to determine the
relationship between hardiness and the amount of
anticipatory nausea and vomiting in patients receiving
cisplatin chemotherapy.

The investigator concluded that

there was no statistically significant relationship
between the independent variable hardiness and the
dependent variable anticipatory nausea and vomiting.
However, small sample size was a major limitation to this
study.

Hardiness may well impact the individual's ability

to buffer stress and symptom development when confronted
with an illness, but further research must be conducted to
explore this relationship in more depth.
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APPENDICES

APPENDIX A

Demographic and Related Data
Please answer each question as accurately as possible.
1.

Age;___________ years (to the nearest year) .

2.

Gender:

3.

Marital status:

1

male

2

female

1___ Married
2___ Single/divorced/widowed,
3___ Single/divorced/widowed,
you are close to
4.

living alone
living with someone

Race :
1___ Caucas ian
2___ Black
3___ Hispanic
4___ Asian
5___ Native American
6___ Other (please identify)_______________________

5.

Highest level of education completed;
1___ Less than high school
2___ High school
3
Partial college education (3 years or less)
4___ College education (4 years)
5___ Beyond 4 years of college

6.

Which ethnic group do you identify with?

7.

Has any one close to you ever received chemotherapy
for the treatment of cancer?
1___ Yes
2
No
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8.

If answered "yes" to item 7:
Did this person experience any distressing symptoms
during their chemotherapy?
1___ Yes
2___ No

9.

If answered "yes" to item 8:
What were the distressing symptoms that person
experienced?
1___ Anorexia
2___ Nausea
3___ Vomiting
4___ Hair loss
5___ Weakness/fatigue
6___ Stomatitis
7___ Pain at injection site
8___ Bruising
9___ Bleeding
10
Others

10.

Have you had any past chemotherapy treatments
(prior to this course of therapy)?
1___ Yes
2___ No

11.

If answered "yes" to item 10:
Did you experience any distressing symptoms during
that chemotherapy treatment regime?
1___ Yes
2___ No

12.

If answered "yes" to item 11:
What distressing symptoms did you experience during
that chemotherapy regime?
1___ Anorexia
2___ Nausea
3___ Vomiting
4___ Hair loss
5___ Weakness/fatigue
6___ Stomatitis
7___ Pain at injection site
8___ Bruising
9___ Bleeding
10
Others
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13.

With the present chemotherapy treatments you are
undergoing, did you experience any nausea and
vomiting before the very first treatment?
1___ Yes
2___ No

14.

With the present chemotherapy treatments you are
undergoing, how much nausea do you experience in the
two days before coming in for treatment?
1___ I
2___ I
3___ I
4___ I

15.

do not experience any nausea.
experience only mild distress from nausea.
experience moderate distress from nausea.
experience severe distress from nausea.

With the present chemotherapy treatments you are
undergoing, how much vomiting do you experience in
the two days before coming in for treatment?
1___ I
2___ I
3___ I
4___ I

do not experience any vomiting.
experience only mild distress from vomiting.
experience moderate distress from vomiting.
experience severe distress from vomiting.
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APPENDIX B

Chart Review Form
1.

Cycle number of chemotherapy this admission;
1___ Cycle
2___ Cycle
3___ Cycle
4___ Cycle

2.

two
three
four
five

Dose of cisplatin to be received this cycle of
chemotherapy:
1___ 70-79 mg/m2
2___ 80-89 mg/m2
3___ 90-99 mg/m2
4____100-109 mg/m2
5___ > 110 mg/m2

3.

Drug protocol for the administration of cisplatin this
chemotherapy cycle:
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4. Drug protocols for the administration of cisplatin
the previous chemotherapy cycles:
Cycle 1:

Date:

Cycle 2:

Date:

Cycle 3:

Date;

Cycle 4:

Date:

Primary site of cancer:
1___ Bladder
2___ Testicle
3___ Ovary
4___ Head/Neck
5___ Cervix
6___ Lung
7___ Breast
8
Other
6.

Is metastatic disease present?
1
2

7.

Yes
No

If item "6" is Yes, identify area/s of metastatic
disease:
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APPENDIX C

Patient Questionnaire
Please answer each question as accurately as possible.
1.

How much nausea did you experience during the first
week
after your last chemotherapy treatment?
1___ I
2___ I
3___ I
4___ I

2.

How much vomiting did you experience during the first
week after your last chemotherapy treatment?
1___ I
2___ I
3___ I
4___ I

3.

did not experience any nausea.
experienced only mild distress from nausea.
experienced moderate distress from nausea.
experienced severe distress from nausea.

did not experience any vomiting.
experienced only mild distress from vomiting.
experienced moderate distress from vomiting.
experienced severe distress from vomiting.

Did you take any medication to prevent or control
nausea and vomiting the first week after your last
chemotherapy treatment?
1___ I did not take any medication to prevent or
control nausea and vomiting.
2___ I took medication to prevent or control nausea
and vomiting one to two times in a twenty-four
hour period.
3___ I took medication to prevent or control nausea
and vomiting three to four times in a twenty-four
hour period.
4___ I took medication to prevent or control nausea
and vomiting more than four times in a twentyfour hour period.
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If you took medication to prevent or control nausea
and vomiting after your last chemotherapy, please
complete the following information;
1 Name of medication:____

____

2 Dose of medication if known:
3 How often you took the medication:

YOU HAVE COMPLETED THIS QUESTIONNAIRE.
PLEASE CHECK AND
MAKE SURE YOU HAVE ANSWERED ALL THE QUESTIONS
THAT APPLY TO YOU.
THANK YOU!1 ! !
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APPENDIX D

Health Related Hardiness Scale
Number
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2

3

4

5

G

___

2.

1can avoid illness,ifItake care ofmyself.

1

2

3

4

5

G

___

3.

Ifinditdifficultto imagine enthusiasm aboutgood
health.

1

2

3

4

5

G

___

4.

Luck ploys abigport indetermininghow soon 1
willrecover from an Illness.

I

2

3

4

5
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S
.

No matter how hard 1try to maintain my henllh,
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e.
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2

3

4

S
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_

G.

Iam incontrolof my health.

I

2

3

4

5

fi __

7.

1admire people who work hard toImprove their
health.

1

2

3

4

5

G ___

8. .
I
tismore important lohnve financialsecurity
than goodhealth.

1

2

3

4

5

G ___

9. The ideas about healthpromotion and illness
prevention aresocialinventionstolimitfreedom
of action.

1

2

3

4

5

6
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10.

My good health i
slargely a matter ofgood
fortune.
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Changes takingplace Inhealthcareare not
exciting tome.
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G
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-
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G

___

17.

Most things thataffect my healthhappen to me by
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G

_
_
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mental andphysicalwell-being.
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_
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23.

1am not Interested Inexploringnew health care
regimensorprograms to Improve my health.

2

3

4

5

G

24.

A close relationship with my familyhasno effect
on my health.

2

3

4

5

G

25.

The onlyreason tobe Involved Inthehealth
promotion movement IstoInercnse my lifespan.

___
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4

28. Tliecurrent focuson licniUlipromotion isa fad
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inlwillprobably disappear.

4

29.

No matter how hard Iwork topromote health for
society.I
tnever seems to improve.

4

30.

Our society holds no worthwhile goalsorvalues
abouthealth.

2

3

4

5

6

31.

I
fItake theright actions, Ican stayhealthy.

2

3

4

5

G

32.

1getexcited about thepossibilityofImproving my
health.

2

3

4

S

6

33. Iam determined tobe as healthyasIcanbe.

2

3

4

5

G

34. When my health Isthreatened, Iview itas a
challenge that must be overcome.

2

3

4

5

6

35. Ireadeverything Ican abouthealth.

2

3

4

5

G

3G. 1canbe ashealthy osIwant tobe.

2

3

4

5

G

37.

Iseenothing wrong with taking riskswith my
health.

38.

When something goes wrong with my health,1do
everythingIcan toget at theroot of theproblem.

2

3

4

5

39.

Ihave littleinfluence over my health.

2

3

4

5

40.

Adequate restIspart of my dailyroutine.

*• Copyright 1988,Susan F
.
.Pollock,Ph.D.

YOU HAVE COMPLETED THIS QUESTIONNAIRE.
PLEASE CHECK AND
MAKE SURE YOU HAVE ANSWERED ALL QUESTIONS.
THANK YOU! ! ! !
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RHODES INV-FORM 2
I D. N u m b er.
Directions: Draw a circle around or mark through the se n te n c e in ea ch row that m ost
clearly co rre sp o n d s to your ex p erien ce. P le a se m ake one mark on each line.

Time ol C T,

I threw up five-six tim es
during the last 12 hours.

I threw up three-four tim es
during the last 12 hours.

I threw up one-tw o tim es
during the last 12 hours.

During the last 12
I h ave not felt an y distreBi
from retching or dry h e a v e s.

During the last 12 hours,
h a v e felt mild distress
retching or dry h ea v es.

During the last 12 hours
I h a v e felt m oderate
d istress from retching or
dry h e a v e s.

During the last Ig^tTurs, i
h a v e felt (
from retctjirtg’or dry h ea v es.

During th e last 12 hours
I h ave felt a s se v e r e
d istress from retching or
dry h e a v e s a s can be.

During th e last 12 hours I
h ave felt a s s e v e r e d istress
from vomiting a s ca n b e.

During the la s K 2 hours
h a v e felt great d istress
from vomiting.

During the last 12 hours I
h a v e felt m oderate d is tc e ^
from vomiting.

During the last 12 hours
I h a v e felt mild d istress
from vomiting

During the last 12 hours I
h ave not felt any d istress
from vomiting.

I h a v e not felt n a u se a te d
or sick at my sto m a ch
during th e last 1 2 hours.

I h a v e felt n au seated or sick
at m y sto m a ch for o n e hour
or le s s during the last 12
hours.

s e a t e d or sick
lach for two-three
12 hours.

I h ave felt n au seated or sick
at m y stom ach four to six
of the last 12 hours.

I h ave felt n a u sea ted or sick
at my stom ach more than
six of the last 12 hours.

During the last 12 hours I
have not felt an y d istre ss
from n a u se a /sic k n e ss at my
stom ach.

During the last 12 h o u r^
h a v e felt mild d istr e^
from n a u se a or sigk fiess at
my stom ach .

During th e last 12 h ^ r s
have felt m oderate d istress
from n a u se a or sic k n e ss ;
my stom ach .

During the last 12 hours I
h a v e felt great d istress
from n a u se a or sic k n e ss at
ny stom ach.

During the last 12 hours I
have felt a s se v e r e d istress
from n a u se a or sic k n e ss at
my stom ach a s can be.

During th e last 12 hours, I
produced a very large (3
cu p s or m ore) am ount e a c h
tim e 1 threw up.

During
12 hours, I
produeiM a large (2-3 cups)
arndunt e a c h time I threw

During the last 12 hours, I
produced a m oderate (%-2
cu p s) am ount ea c h tim e I
threw up.

D u rir tg ^ e last 12 hours, I
producebka sm a// (up to
'/2 cup) arnbypt ea c h tim e I
threw up.

During the last 12 hours, I
did not throw up.

I h a v e felt n a u se a te d or s
at my sto m a ch se v e n /d r
m ore different tim ^g^uring
the last 12 h o u îs

I h a v e felt n a u se a te d or sick
at my sto m a ch five-six dif
ferent tim es during the last
12 hours.

I h a v e felt n a u sea te d or sick
at my stom ach three-four
different tim es during the
last 12 hours.

I h a v e felt nauseated^b^sick
at my stom ach one-twoS
ferent tim es during the la st
12 hours.

I have not felt n a u sea ted or
sick at my stom ach during
the last 12 hours.

During thp/fast 12 hours
I ha\iej)fad NO period s of
retcljiffg or dry h e a v e s withopt^ringing anything up.

During the last 12 hours I
h a v e had 1-2 periods of
retching or dry h e a v e s with
out bringing anything up.

During the last 12 hours I
h ave had 3 -4 periods of
retching or dry h e a v e s with
out bringing anything up.

During the last 12 hours I
h a v e had 5 -6 periods of
retching or dry h e a v e s with
out bringing anything up.

D u rin gS i^ last 12 hours I
have hao% or m ore periods
of retching oN(Jry h e a v e s
without bringing êüîjrihing up.

tir
12 hours. '

5ven or m ore
the last

T im e _______

D a te.

^ e fell

atrn^s^
of t h a ^

Copyright 1 9 8 3 . Curators of tvtissouri.

Instructions for administering and scoring may be obtained from V. Rhodes or J. Lay, S221
University of Missouri, Columbia, MO
65211; 314-882-0204.

did n o ,^ h f 6 w u p d u rin g
1 2 h o u rs.

Verna A. R h o d es, RN,

School of Nursing Building,

INV SCALE
C o m p le te o n e INV S c a le starting
a t 7, 8, o r 9 p.m . th e e v e n in g
follow in g ch em o th era p y
C h o o s e th e b e s t hour for your
s c h e d u le .
B eg in n in g with your c h o s e n hour,
c o m p ie te o n e INV S c a le ev ery 12
h ou rs at th e s a m e clo ck hour for
six tim e s.
E xam p le: 7 PM - 7 AM
8 PM - 8 AM
9 PM - 9 AM

VR:lb
7 /2 1 /8 2

APPENDIX F

Introductory Statement
Hello, I am Colleen Smith, a registered nurse.

I

am conducting a study to find out what people think
about their health and how they feel before getting
their chemotherapy treatments.
I hope that information gained from this study will
help nurses and doctors to better meet the needs of
cancer patients.

In order to conduct my study, I need

several patients to answer a few questions and complete
three brief paper and pencil questionnaires.

Two of the

questionnaires will be mailed to you to be completed in
your home.

These questionnaires will require about 20-30

minutes to complete.

The other questionnaire will be

given to you at the time of your next admission for
chemotherapy.

This questionnaire will require about 5

minutes to complete.
Please understand that at no time will you be
identified and that all information is kept strictly
confidential.
If you are interested in participating, I would like
to leave this consent form for you to read and sign.
will return in a few minutes to pick up the form.
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I

Your

signature on the consent form will indicate your consent
to participate in this study, at which time you will
receive further information and instructions.
Thank you very much for your cooperation.
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APPENDIX G
Consent to Participate in Study
I am aware that this is a study of how people view certain
important issues related to their health. I also
understand that this study will examine how I feel just
before and after I receive my chemotherapy treatment.
I
understand that the knowledge gained is expected to help
nurses and physicians provide health care in a manner
which will be responsive to the needs of patients
receiving chemotherapy.
I also understand that:
1. participation in this study will involve a
brief interview that will be conducted after
I sign the consent form. Participation will also
include three paper and pencil questionnaires to
be completed one time only. The first
questionnaire will deal with general information
about how I feel after my chemotherapy. The
second questionnaire will deal with how I view
certain issues related to my health. Both of
these questionnaires will be mailed to me so I
can complete them in my own home. The third
questionnaire will deal with how I feel just
before I receive my chemotherapy. This
questionnaire will be given to me to complete in
the hospital the day I am admitted to receive my
next chemotherapy treatment.
2.

there are no anticipated physical or emotional
risks as a result of participating in this study.

3.

a summary of the results will be made available
to me upon my request.

I acknowledge that:
I have been given an opportunity to ask questions
regarding this research study, and that these
questions have been answered to my satisfaction.
In giving my consent, I understand that my
participation in this study is voluntary and that I
may withdraw at any time without affecting the care I
receive from my physicians or the staff at
Butterworth Hospital.
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I understand I will receive no payment for my
participation.
Continuing medical care and/or
hospitalization will not be provided free of charge,
nor will financial compensation be available.
The investigator and/or delegated representatives
from Butterworth Hospital and/or the Food and Drug
Administration may inspect any data collected in
relationship to this study where appropriate and
necessary.
The investigator, Colleen Smith, has my permission to
review my chart regarding my chemotherapy drugs and
dosage.
I hereby authorize the investigator to release the
information obtained in this study to scientific
literature.
I understand that I will not be
identified by name.
I may contact Colleen Smith at (616) 732-3541 between
9AM and 5PM Monday through Friday for any questions.
Should I have any questions regarding my rights as a
patient, I may call the Human Rights Committee
Representative at 774-1299.
I acknowledge that I have read and understand the above
information, and that I agree to participate in this
study.

(Witness)

(Participant

(Date)

Signature)

(Date)
(Investigator Signature)
(Date)

_I am interested in receiving a summary of the study
results.
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APPENDIX H

Cover Letter

Date
Subject Name_
Address
Dear
As you recall, you agreed to participate in my research
study while you were at Butterworth Hospital. As a part
of this study, I am asking you to fill out the two
questionnaires which are enclosed. They should require
about 20-3 0 minutes to complete. A stamped, addressed
envelope is provided for you to return the completed
questionnaires to me. Do not sign your name or identify
yourself in any way on the questionnaires.
Please
complete and return them at your earliest convenience.
Also enclosed find a stamped, addressed postcard which
requests information about your next admission for
treatment. Please complete this postcard and drop it in
the mail when you are able to determine the date of your
next admission. This information will enable me to
provide you with the final questionnaire for the study at
the time of your next admission. This questionnaire will
be brief, requiring only about 5 minutes to complete.
Please mail the postcard separate from the questionnaires
you have completed.
I look forward to receiving your completed questionnaires
and postcard soon and to seeing you again in the next few
weeks.
Sincerely,

Colleen Smith, RN, BSN
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